SCHEMBL4558758

SCHEMBL4558758

COc1cc2nccc(Oc3ccc(NC(=S)NC(=O)c4ccc(Cl)cc4)cc3)c2cc1OC

nearest known ligand 0.83

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PDGFRA P16234 14/20 0.83
KIT P10721 4/20 0.83
KDR P35968 12/20 0.74
MET P08581 3/20 0.65
AXL P30530 2/20 0.63
AURKA O14965 1/20 0.62
LCK P06239 1/20 0.62
CSF1R P07333 1/20 0.62
BRAF P15056 1/20 0.62
FLT1 P17948 1/20 0.62
FGFR2 P21802 1/20 0.62
FLT4 P35916 1/20 0.62
TEK Q02763 1/20 0.62
AURKB Q96GD4 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5824387 0.93 PDGFRA (0.87) PDGFRAKITKDRMETAXL
SCHEMBL5825418 0.93 PDGFRA (0.80) PDGFRAKITKDRMETAXL
SCHEMBL5824689 0.92 PDGFRA (0.84) PDGFRAKITKDRMETAXL
SCHEMBL5825815 0.91 PDGFRA (0.77) PDGFRAKITKDRMETAXL
SCHEMBL5824928 0.91 PDGFRA (0.83) PDGFRAKITKDRMETAXL
SCHEMBL5824922 0.91 PDGFRA (0.83) PDGFRAKITKDRMETAXL
SCHEMBL5824959 0.91 PDGFRA (1.00) PDGFRAKITKDRMETAXL
SCHEMBL5825435 0.91 PDGFRA (0.82) PDGFRAKITKDRMETAXL
SCHEMBL5824829 0.90 PDGFRA (0.82) PDGFRAKITKDRMETAXL
SCHEMBL5824538 0.90 PDGFRA (0.79) PDGFRAKITKDRMETAXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7135466-B2 Quinoline and quinazoline derivatives and drugs containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-11-14 US claimed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7135466-B2 Quinoline and quinazoline derivatives and drugs containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-11-14 US disclosed
US-20060211717-A1 Quinoline and quinazoline derivatives and drugs containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-21 US disclosed
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2005-03-03 US disclosed
EP-1447405-A1 QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING AUTO-PHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS KIRIN BEER KABUSHIKI KAISHA (JP) 2004-08-18 EP disclosed
US-20040132727-A1 Quinoline and quinazoline derivatives and drugs containing the same KIRIN HOLDINGS KABUSHIKI KAISHA (JP) 2004-07-08 US disclosed
EP-1243582-A1 QUINOLINE AND QUINAZOLINE DERIVATIVES AND DRUGS CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2002-09-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211717-A1 Quinoline and quinazoline derivatives and drugs containing the same PDGFRA, PDGFRB, PDGFA PDGFRA 1/4885KIT 401/4885KDR 4/4885
US-20040132727-A1 Quinoline and quinazoline derivatives and drugs containing the same PDGFRA, PDGFRB, PDGFA PDGFRA 1/4885KIT 499/4885KDR 5/4885
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors FGFR1, FGFR2, FGFR3 PDGFRA 372/4885KIT 1337/4885KDR 211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.